Replies to post #590049 on NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

30 days

[antihama]

In a previous post (540185), I came up w a scenario of what personnel would be needed for NWBO to stay independent after marketed drug approval by a Regulatory Agency. It wouldn't take many hires to launch the drug. Just a higher up person or so in Regulatory Affairs, QA, Manufacturing, Medical Affairs, Marketing, and Sales and w additional sales peeps coming on board near launch. I felt this was a very plausible scenario. Of course, after approval, NWBO would need to hire a slew of others such as in Clinical. After having this discussion the last time, I was curious what were the job functions of those 15 - 20 persons who worked at NWBO so I joined LinkedIn to try to find out. On initially joining, I was able to see there were about 16 people listed there and nothing stood out that would make me think they want to remain independent but I rationalized they are waiting till MAA/BLA submission to start the hiring process. I tried looking now, and I was unsuccessful in looking at the LinkedIn NWBO to see if they (not Advent) were hiring. I don't know if I was unsuccessful in searching because I only have free membership, or am not a business owner, or just don't know how to navigate the site but I'd be curious to know if NWBO, at this point in time, hired for any of the positions that would be needed to stay as an independent company. It doesn't seem to make sense to hire consultants to perform these functions because that would get really expensive, and I don't think you can have these positions at Advent because even though Advent and NWBO are joined at the hip they are two different entities and I believe there would be some conflict of interest if Advent, as the manufacturing CDMO, fully released drug to market. The correct way would be for Advent to release drug to the Sponsor and Sponsor release drug to market (i.e. no conflict of interest). So in sum, unless these minimal few positions are being hired at NWBO, I'd have to agree w you.

[biosectinvestor]

The subsidiary at this stage is likely only for ongoing innovation. Implementation is more than likely mostly the approval process for inclusion in its actual facility, and that work is likely all done and pending final confirmation, most likely either pending submission or pending approval, or collection of final data. And then implementation which is likely about payments and advent incorporating it into the plants development stages.

I doubt the number of employees remaining at Flaskworks is a determining factor with regard to pricing or a buyout. They already have the patents and are likely well along in terms of validation and probably it is already worked out as to what and when implementation for Sawston will occur. Any acquisition would certainly include that value, up to whatever stage of validation and implementation they are at including the acquisition value and IP value as it pertains to this company owning such IP. This includes also the fact that this technology certainly further extends NWBO’s likely control over the commercial implementation of DCVax in all of its forms for many more years since those patents are virtually all process patents and the Flaskworks patents extend and improve on all of those patents.

[skitahoe]

I think that they have something like a dozen people working on the EDEN unit in Boston and Sawston. It is still the key to major future growth, being the EDEN unit.

Gary